Efficacy and safety of switching from baricitinib to ritlecitinib in severe alopecia areata
This study investigates the efficacy and safety of ritlecitinib, a Janus kinase (JAK)3/TEC inhibitor, in patients with severe alopecia areata (AA) with inadequate or no response to baricitinib, a JAK1/2 inhibitor. Our results indicate that treatment with ritlecitinib not only leads to significant improvements in hair regrowth and quality of life but also positively impacts the psychological well-being of patients with severe AA. Our study highlights that an inadequate or no response to one JAK inhibitor does not necessarily predict failure with another.
Authors
- Xiaoqing Lv (ORCID: https://orcid.org/0000-0002-8681-1271)
- Chao Ji (ORCID: https://orcid.org/0000-0002-2282-3505)
- Jing Mao (ORCID: https://orcid.org/0009-0001-8796-2311)
- Ze‐Hao Zhuang (ORCID: https://orcid.org/0000-0001-7323-2900)
- Ying Chen (ORCID: https://orcid.org/0009-0005-8351-6620)
- Ting Gong
- Qiuyun Xu
- Siyi Bao
Institutions
- Fujian Medical University (CN)
- Capital Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Nanchong Central Hospital (CN)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1093/ced/llae548
- Citations
- 7
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.75